Chipscreen sets pace for biotech IPOs in Shanghai

Shanghai IPO values Chipscreen at $1.2B, opening the door for biopharma listings on the STAR market

Qpex Biopharma to Provide First Public Presentations of Preclinical Data on the Novel Ultra-Broad-Spectrum Beta-lactamase Inhibitor QPX7728 for IV and Oral Products at 2019 ASM Microbe Meeting

SAN DIEGO, June 13, 2019 /PRNewswire/ -- Qpex Biopharma today announced that preclinical data on its investigational beta-lactamase inhibitor QPX7728 will be featured in several presentations at the 2019 ASM Microbe Meeting to be held June 20-24 in San Francisco, CA.

Chipscreen set to test Shanghai's new innovation board

Chipscreen could soon become the first biotech to list on the Shanghai Stock Exchange’s new science and technology innovation board after its application was approved this week.

新突破！中山医院王春生团队实施亚洲首例经导管二尖瓣置换术，跻身全球研究第一方阵

王春生教授、魏来副教授与医疗创新企业合作研发成功Mi-thos经导管二尖瓣置换系统，成为亚洲第一款获批开展探索性临床应用的经导管二尖瓣置换系统，这次手术的成功实施也标志着中国已跻身世界TMVR研究领域的第一方阵。

广安摩珈生物科技有限公司生物技术产业化项目 环境影响评价全文的公示

一、项目名称及概要
（1）项目名称：生物技术产业化项目；
（2）项目性质：新建；
（3）建设单位：广安摩珈生物科技有限公司；
（4）拟建设地点：广安经济技术开发区新桥园区；
（5）拟投资规模：15000万元；

Qpex Biopharma Licenses Polymyxin Antimicrobial Program from Monash University to Address Drug-Resistant Infections

SAN DIEGO, April 30, 2019 /PRNewswire/ -- Qpex Biopharma today announced the closing of a license agreement from Monash University providing Qpex a portfolio of next-generation polymyxin antimicrobials focused against highly drug-resistant gram-negative pathogens. The exclusive license includes worldwide rights to develop and commercialize polymyxin antimicrobials in multiple territories.